Press Releases

Sep 18, 2018

LivaNova Launches International Pivotal Study Evaluating Use of Autonomic Regulation Therapy for Heart Failure

LONDON --(BUSINESS WIRE)--Sep. 18, 2018-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced the first successful implantation of the VITARIA ® System in a patient enrolled in the A uto n omic Regulation Th erapy to E nhance M yocardial Function and Reduce...Read More
Sep 10, 2018

LivaNova Welcomes NICE Interventional Procedures Guidance on Sutureless Aortic Valve Replacement

Announcement comes as Company completes enrollment in PERSIST-AVR Trial for Perceval sutureless aortic valve LONDON --(BUSINESS WIRE)--Sep. 10, 2018-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, welcomes the recently updated interventional procedures guidance for...Read More
Sep 04, 2018

LivaNova VNS Therapy System for Drug-Resistant Epilepsy Could Save $77,000 Per Patient Over Five Years

Analysis finds overall cost savings far exceed system-related costs LONDON --(BUSINESS WIRE)--Sep. 4, 2018-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that a new cost analysis found the Company’s Vagus Nerve Stimulation Therapy ® (VNS Therapy) System...Read More
Aug 22, 2018

LivaNova to Present at Morgan Stanley Global Healthcare Conference

LONDON --(BUSINESS WIRE)--Aug. 22, 2018-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Damien McDonald , Chief Executive Officer of LivaNova , will present at the Morgan Stanley 16 th Annual Global Healthcare Conference on Thursday, Sept....Read More
Aug 06, 2018

LivaNova Concludes PRELUDE Study for Transcatheter Mitral Valve Replacement System

Company now focused on INTERLUDE CE Mark trial, building upon positive patient outcomes LONDON --(BUSINESS WIRE)--Aug. 6, 2018-- LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology company, today announced the conclusion of the PRELUDE feasibility study for its Caisson Transcatheter...Read More
Aug 01, 2018

LivaNova Reports Second Quarter 2018 Results

LONDON --(BUSINESS WIRE)--Aug. 1, 2018-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended June 30, 2018. For the second quarter of 2018, worldwide sales from continuing operations were $287.5 million , an increase...Read More
Jul 03, 2018

LivaNova to Host Conference Call for Second Quarter 2018 Results

LONDON --(BUSINESS WIRE)--Jul. 3, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, will host a conference call to discuss its second quarter 2018 results on Wednesday, Aug. 1, 2018 at 1 p.m. London time ( 8 a.m. Eastern Daylight Time )....Read More
Jun 14, 2018

LivaNova Receives FDA Clearance and Completes First Implant for its MEMO 4D Semi-rigid Mitral Annuloplasty Ring

LONDON --(BUSINESS WIRE)--Jun. 14, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced it received FDA 510(k) clearance for its MEMO 4D ® semi-rigid mitral annuloplasty ring and confirmed the first implantation of the device.

...Read More
Jun 13, 2018

LivaNova Welcomes William Kozy to Board of Directors

LONDON --(BUSINESS WIRE)--Jun. 13, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today announced that William A. Kozy , retired Executive Vice President and Chief Operating Officer at Becton, Dickinson and Company

...Read More
Jun 11, 2018

LivaNova’s Perceval Sutureless Aortic Heart Valve Approved in Japan

LONDON --(BUSINESS WIRE)--Jun. 11, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced that Japan’s Ministry of Health, Labour and Welfare has approved the Company’s Perceval ® sutureless aortic heart valve to treat aortic

...Read More
May 31, 2018

LivaNova to Present at the Jefferies and Goldman Sachs Conferences

LONDON --(BUSINESS WIRE)--May 31, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced company executives will present at two upcoming healthcare conferences. Chief Executive Officer Damien McDonald and Chief Financial Officer

...Read More
May 30, 2018

LivaNova Comments on the U.S. Centers for Medicare & Medicaid Services’ Reconsideration of its National Coverage Determination for VNS Therapy for Treatment-Resistant Depression

LONDON --(BUSINESS WIRE)--May 30, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today issued a statement in regard to the U.S. Centers for Medicare & Medicaid Services’ (“CMS”) publication of a tracking sheet to reconsider its National

...Read More
May 02, 2018

LivaNova Reports First Quarter 2018 Results

LONDON --(BUSINESS WIRE)--May 2, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2018. For the first quarter of 2018, worldwide sales from continuing operations were...Read More
Apr 30, 2018

LivaNova Completes Sale of Cardiac Rhythm Management Business to MicroPort Scientific Corporation

LONDON --(BUSINESS WIRE)--Apr. 30, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced it has successfully completed the divestiture of its Cardiac Rhythm Management (“CRM”) business to MicroPort Scientific Corporation (HK:...Read More
Apr 26, 2018

LivaNova Announces One-Millionth Inspire Adult Oxygenator Patient

LivaNova celebrates cardiac perfusion milestone, surpassing one million worldwide clinical cases LONDON --(BUSINESS WIRE)--Apr. 26, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced its Inspire® innovative adult oxygenator...Read More
Apr 17, 2018

LivaNova Receives CE Mark for VNS Therapy SenTiva Generator and Next-Generation Programming System for Treatment of Epilepsy

LONDON --(BUSINESS WIRE)--Apr. 17, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced it received CE Mark for its Vagus Nerve Stimulation Therapy ® (“VNS Therapy”) System comprised of the SenTiva ® generator and...Read More
Apr 05, 2018

LivaNova to Host Conference Call for First Quarter 2018 Results

LONDON --(BUSINESS WIRE)--Apr. 5, 2018-- LivaNova PLC (NASDAQ:LIVN) ("LivaNova" or the "Company"), a market-leading medical technology company, will host a conference call to discuss its first quarter 2018 results on Wednesday, May 2, 2018 at 2 p.m. London time (9 a.m. Eastern Daylight Time)....Read More
Apr 04, 2018

LivaNova Completes Acquisition of TandemLife

LONDON --(BUSINESS WIRE)--Apr. 4, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced it closed its acquisition of TandemLife. Previously, on Feb. 14 , LivaNova announced its intent to acquire TandemLife, a privately held...Read More
Mar 29, 2018

LivaNova Bicarbon Aortic Valves Receive CE Mark for Expanded Use Labeling with Lower-Dose Blood Thinners in Low-Risk Patients

LONDON --(BUSINESS WIRE)--Mar. 29, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, has received CE Mark approval for its Bicarbon ® aortic valves for use with low-dose anticoagulant therapy....Read More
Mar 28, 2018

LivaNova Commences Clinical Study to Evaluate Treatment Outcomes for Novel Microburst VNS Therapy System

LONDON --(BUSINESS WIRE)--Mar. 28, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced the launch and enrollment of the first patient in a clinical study to examine the use of LivaNova’s new Microburst Vagus Nerve Stimulation...Read More
Mar 22, 2018

LivaNova Announces Enrollment for PERFECT Perceval Valve Clinical Trial in China

Pre-market trial to demonstrate safety and effectiveness of Perceval sutureless aortic heart valve LONDON --(BUSINESS WIRE)--Mar. 22, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, has announced the first patient enrollment in the...Read More
Mar 20, 2018

LivaNova to Present at the Needham & Company Healthcare Conference

LONDON --(BUSINESS WIRE)--Mar. 20, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced Thad Huston , Chief Financial Officer of LivaNova , will present at the Needham & Company Healthcare Conference in New York on Tuesday,...Read More
Mar 08, 2018

LivaNova Enters into Definitive Agreement to Divest Its Cardiac Rhythm Management Business Franchise to MicroPort Scientific Corporation

LONDON --(BUSINESS WIRE)--Mar. 8, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova”) today announced that it has entered into a definitive Stock and Asset Purchase Agreement (“Purchase Agreement”) to divest its Cardiac Rhythm Management business franchise to MicroPort Scientific Corporation...Read More
Feb 28, 2018

LivaNova Reports Fourth Quarter and Full-Year 2017 Results

LONDON --(BUSINESS WIRE)--Feb. 28, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today reported results for the quarter and full-year ended December 31, 2017. For the fourth quarter of 2017, worldwide sales from...Read More
Feb 15, 2018

LivaNova to Present at the Barclays and Cowen Conferences

LONDON --(BUSINESS WIRE)--Feb. 15, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced company executives will present at two upcoming healthcare conferences taking place on Tuesday, March 13 ....Read More
Feb 14, 2018

LivaNova to Acquire TandemLife

Company will add advanced cardiopulmonary temporary support solutions to its portfolio LONDON --(BUSINESS WIRE)--Feb. 14, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced it has entered into an agreement to acquire...Read More
Feb 01, 2018

LivaNova Announces CE Mark for PureFlex Arterial Cannulae Line for Conventional Cardiac Surgery

Company celebrates new design that delivers improved flexibility, clarity and control LONDON --(BUSINESS WIRE)--Feb. 1, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced it has achieved CE Mark for its new PureFlex TM line...Read More
Jan 24, 2018

LivaNova to Host Conference Call for Fourth Quarter and Full-Year 2017 Results

LONDON --(BUSINESS WIRE)--Jan. 24, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, will host a conference call to discuss its fourth quarter and full-year 2017 results on Wednesday, Feb. 28, 2018 at 8 a.m. CST ( 2 p.m. GMT )....Read More
Jan 11, 2018

LivaNova Initiates BELIEVE Aortic Heart Valve Study in the U.S. and Canada

Company is advancing clinical research with three aortic valve studies LONDON --(BUSINESS WIRE)--Jan. 11, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced that the first patient has been enrolled in the Be havior of Valve...Read More
Jan 08, 2018

LivaNova Announces Matthew J. Dodds as Senior Vice President, Corporate Development

LONDON --(BUSINESS WIRE)--Jan. 8, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced Matthew J. Dodds has joined the Company as Senior Vice President, Corporate Development. In this role, Dodds is responsible for Business...Read More
Jan 04, 2018

LivaNova Commences Global RESTORE-LIFE Study for Treatment-Resistant Depression

First patient enrolled to assess the effectiveness and efficiency of VNS Therapy as adjunctive treatment LONDON --(BUSINESS WIRE)--Jan. 4, 2018-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced the launch and enrollment of the...Read More